

NUTRI NEWS



**Douglas
Laboratories®**
*Raising the Standard for
Nutrition and Wellness™*

Recent health and nutrition information from Douglas Laboratories

Winter 2006

Phytotherapeutic Management of Endocrine Dysfunctions

Joseph J. Collins, N.D.

When Hormones Are Not Enough

Current perceptions of endocrine dysfunctions often place great weight on serum or salivary levels of hormones as the most accurate indication of hormone function. This becomes troubling when clinicians observe an increasing percentage of patients who have hormone levels in the "normal range", but still have significant symptoms of hormone dysfunction. Increased understandings of insulin resistance has raised awareness that while measuring hormone levels is important, just as important is the physiological response to those hormones, or in many cases, the lack of physiological response. To the clinician managing menopause, andropause, PMS/PMDD and PCOS patients the incongruence between objective data (lab tests) and subjective data (patient symptoms), can best be explained to patients by introducing the concepts of cellular resistance and sensitivity as well as hormone agonists and antagonists. When explaining "hormone function" to patients, an effective educational phrase is "It's not just the levels, it's the listening." Collectively, essential fatty acids and targeted phytotherapeutics increase cellular ability to "listen" to hormone messages.

While resistance may be therapeutically approached through increasing essential fatty acids such as docosahexaenoic acid, agonists and antagonists may be therapeutically approached with targeted phytotherapeutic agents. The most effective first line of phytotherapeutic agents for the management of menopause, andropause, PMS/PMDD and PCOS patients primarily target the function of endogenous androgens, estrogens, and progesterogens. While classic endocrinology models may explain some actions of phytotherapeutic agents which affect hormone function, the phytotherapeutic management of endocrine dysfunctions require as much of an understanding of phytotherapy as it does endocrinology.

Hormones are nothing more than chemical messengers that, in most cases, originate in one place, such as ovaries, testes, adrenal glands, or other endocrine tissue, and exert their affect at a different site, such as brain, heart, bone, blood vessels, or other tissue – including other endocrine tissues. There are a number of different ways in which cells

receive messages and respond to hormone messengers. Endocrine, as noted, is defined as cellular response to a hormone originating from distant endocrine cells. Autocrine is defined as cellular response to a hormone that originates from the cell itself, such as the synthesis of estrogens from androgens within breast tissue. Paracrine is defined as cellular response to a message originating from nearby tissue, such as breast tissue converting androgens to estrogens and secreting them to affect adjacent cells. Like endocrine responses, autocrine and paracrine responses are responses to substances originating from the organism itself. They are from distant cells, the cell itself, or nearby cells respectively. Responses which originate from outside the organism, and from plant sources specifically, may be termed "phytochrine".

Phytochrine, like endocrine, may be used as a means of describing how cells respond to chemical messages. In that regard, the variable actions of plants with phytochrine activity must be recognized. The actions of phytochrines may broadly be divided into agonists and antagonists. An agonist to a specific hormone works with that hormone,

Continued on page 2

INSIDE THIS ISSUE

Phytotherapeutic Management of Endocrine Dysfunction:

When Hormones Are Not Enough	page 1
Phytochrine Classification	page 2
Clinical Applications of Phytotherapeutics in Endocrine Dysfunction	page 3
Phytotherapeutics to Restore Optimal Estrogen Function	page 3
Phytotherapeutics to Restore Optimal Progesterone Function	page 3
Phytotherapeutics to Restore Optimal Testosterone Function	page 4
Phytotherapeutics to Quench Excessive Testosterone Function	page 6
Conclusion	page 6

Women, Take Heart. Soy Isoflavones as Self-Care for Menopausal Symptoms and Disease Risks.	page 5
---	--------

thereby supporting, restoring, enhancing or substituting for one or more of its functions. An antagonist to a specific hormone works against that hormone, diminishing, quenching or blocking one or more affect of that hormone.

Phytocrine Classification

Another way to classify phytocrines can be based on the way in which they exert their actions. Some phytocrines bind to hormone receptors, some increase the ability of the body to make hormones, and some mimic important hormone functions. Any given plant that has phytocrine activity may affect cells in one or more of these fashions. In classifying phytocrines based on the way in which they exert their actions, we can recognize three primary classes; phytohormones, phytohormonogenics, and functional mimetics of hormones.

Phytohormones are plant constituents with hormone-like structures. Sometimes referred to as phytosterols, they possess weak hormone activity. They may bind to hormone receptors resulting in the same type of response that the hormone would cause. Even though the type of response is the same, the intensity may be weaker, and/or the duration of the response (retention time) may be different. Further classifications of phytohormones include the widely recognized term "phytoestrogens", which bind to estrogen receptors. Additional phytohormones include "phytoprogestogens", which bind to progesterone receptors and

"phytoandrogens", which bind to androgen receptors. A clinically valuable group of "phytoantiandrogens" bind to androgen receptors, but exert an antagonistic functional response. Currently recognized phytoestrogens include various isoflavones such as genistein and daidzein from soy, biochanin A, & formononetin from red clover, and puerarin & 3'-methoxypuerarin from kudzu (*Pueraria lobata*).

Phytohormonogenics are plants which augment the ability of the body to generate hormones. Classically, phytohormonogenic plants are considered to have adaptogenic properties. These plants may have a direct effect on target tissue, increasing the hormone production within specific endocrine tissue, or they may have an affect on the hypothalamic-pituitary-adrenal axis and/or the hypothalamic-pituitary-gonadal axis, in effect increasing adrenotrophic and/or gonadotrophic hormones or functions. Clinically valuable phytohormonogenics include "phytoprogestogen-ogenics", which increase endogenous progesterone production and "phytoandrogen-ogenics", which increase endogenous androgen production. Due to current perception of estrogen as being dangerous, "phytoestrogen-ogenics", which can increase endogenous estrogen production are rarely used or promoted to patients. The "phytoandrogen-ogenic" properties of *Withania somnifera* can be attributed to its activation of the hypothalamic-pituitary-gonadal axis, which increases gonadotrophic hormones.¹ The active constituent of *Coleus forskohlii*, forskolin has a direct effect on progesterone producing tissues.^{2,3}

One of the most intriguing classes of phytocrines is the "Functional Mimetic of Hormones", which are plants which mimic one or more hormone functions. The functional mimetics of hormones can cause the same physiological response of the hormone they are mimicking. They do not need to bind to a hormone receptor to cause a similar functional response as the hormone. These phytocrines may mimic one or more functions of a hormone. These phytocrines may also be considered as functional agonists. Functional mimetics are clinically valuable for targeted functions of testosterone, progesterone and estrogen without binding to hormone receptors. An example of an herb used as a functional mimetic of estrogen is *Bacopa monniera*⁴, which mimics the abilities of estrogen to help the body adapt to both acute and chronic stress as well as maintain cognitive function, though it does not bind to estrogen receptors. Though black cohosh (*Cimicifuga racemosa*) has periodically been described as having phytoestrogen properties, due to its ability to diminish menopause symptoms that are associated with estrogen deficiency, we now know that *Cimicifuga racemosa* does not universally bind to either of the known estrogen receptors,^{5,6} though it may have selective estrogen receptor modulator (SERM) activity specific to bone and hypothalamo/pituitary tissues.⁷

As the traditional perceptions of phytotherapeutic agents as only "phytohormones" is expanding to include phytohormonogenics and functional mimetics of hormones,

NUTRI NEWS

Volume 8
Number 1

Editor In Chief Andrew D. Halpner, Ph.D.

Assistant Editor Michael Traficante

Assistant Editor & Research Natalie Shamitko

Technical Advisors/Contributors: ..James Wilson, Ph.D.

Martin P. Gallagher, M.D., D.C.

Vern S. Cherewatenko, M.D., MEd

Joseph Collins, N.D.

Ronald Klatz, M.D., D.O.

Robert Nash, M.D.

Van D. Merkle, D.C.

Contact Us:

NutriNews Inquiries

600 Boyce Road • Pittsburgh, PA 15205

Phone: (412) 494-0122 • Fax: (412) 278-6804

Email: nutrinews@douglaslabs.com

Canadian Inquiries

Toll-Free: 866-856-9954

Email: info@douglaslabs.ca

[View back issues of NutriNews online at www.douglaslabs.com](http://www.douglaslabs.com)

the recognition of different classes of phytoestrogens allows us to use phytotherapeutic agents for endocrine dysfunctions with greater clinical efficacy.

Clinical Applications of Phytotherapeutics in Endocrine Dysfunction

Phytotherapeutic applications designed to support normal function of estrogen can now address all of the needs of estrogen. Traditional approaches for weak estrogen function were thought to be solely phytoestrogens, and targeted primarily vasomotor symptoms. We now realize that Black Cohosh acts as a functional mimetic that does not always require estrogen receptors to exert its effects. Additional functional mimetics of estrogen, such as Bacopa, can support other tissues that respond to estrogen. In addition to relieving hot flashes and night sweats, formulations can now support healthy function of bone, heart, brain, breasts, vagina and other estrogen sensitive tissues. Phytotherapeutics to support progesterone function promote endogenous progesterone production as well as support and mimic the anti-inflammatory, anti-allergy and anti-autoimmune properties of progesterone, in addition to supporting uterine, cardiovascular, bone and neuro-cognitive functions.

Phytotherapeutics designed to support androgen function promote endogenous testosterone production, mimic the anabolic, strengthening, and stimulating effects of testosterone, and support healthy brain, nerve, muscle, immune, cardiovascular, and other systems prone to atrophy, senescence or weakness.

Clinical application requires recognition that the synergy of phytomedicines has the same validity as the synergy of pharmaceutical agents.⁸ The synergism seen in phytotherapeutic formulations manifests in such a way that the clinical efficacy of multiple constituents act collectively to create an effect which is greater than the sum of the effects that each is able to create independently. In this fashion, while Bacopa, Schisandra and Cranberry fruit each have the ability to positively influence neuro-cognitive function, clinical observation reveals more rapid onset of these influences with increased efficacy when these components are part of a synergistic formulation.

Phytotherapeutics to Restore Optimal Estrogen Function

The foundation for phytotherapeutics to restore optimal estrogen function includes the isoflavones from soy (*Glycine max*), kudzu (*Pueraria lobata*) and red clover (*Trifolium pretense*), which have the ability to diminish menopausal symptoms and support maintenance of bone mineral density. These phytoestrogens may also help protect the cardiovascular system, support the immune system, inhibit angiogenesis, and protect against oxidative damage as antioxidants. Therapeutic dosages of Black Cohosh (*Cimicifuga racemosa*) effectively diminish menopause symptoms such as hot flashes, night sweats, insomnia, irritability, heart palpitations, and headaches without

always affecting estrogen receptors as noted.

The therapeutic effects that hops, (*Humulus lupulus*) has in reducing hot flashes in menopausal women and its efficacy in mood disturbances such as restlessness and anxiety, and sleep disturbances appear to be due to the phytoestrogenic activity of constituents such as 8-prenylnaringenin. Sage (*Salvia officinalis*) contains phytoestrogen substances that are effectively used to treat hot flashes and to decrease perspiration in both daytime and night-time excessive sweating. The positive effects of Sage on the nervous system include both memory-improving properties and calming actions, the latter of which have been attributed to its ability to bind to the GABA/benzodiazepine receptor complex in brain tissue.

The neuro-cognitive supporting actions of Schisandra (*Schisandra chinensis*) may be associated with its affect on serotonin and GABA receptors,⁹ while its ability to manage cardiovascular symptoms, especially those associated with menopause, may be attributed to its ability to activate estrogen receptors and affect nitric oxide-mediated vasorelaxation.¹⁰ Thus, Schisandra may express phytoestrogen properties, and be a functional mimetic of estrogen in regard to serotonin and GABA receptors.

The ability of Cranberry fruit (*Vaccinium macrocarpon*) to protect neuronal and cognitive brain function, as well as cardiovascular health is associated with antioxidant activity, mimicking the estrogen receptor-independent antioxidant activities or estradiol.^{11,12,13} At present, the neuro-protective antioxidant properties¹⁴ and nootropic actions¹⁵ of Bacopa (*Bacopa monniera*) are not associated with estrogen-receptors, suggesting functional mimetic attributes. Since Don Quai (*Angelica sinensis*) has weak estrogen receptor binding capacity¹⁶ it may be considered a phytoestrogen which may explain its traditional use to increase vaginal lubrication, though it does not produce estrogen-like responses in endometrial thickness.¹⁷ The action of increased bone formation by ferulic acid, a constituent of Don Quai, is different from the actions estrogens,¹⁸ suggesting functional mimetic of estrogen properties.

Phytotherapeutics to Restore Optimal Progesterone Function

Since there is essentially no ovarian secretion of progesterone during the follicular phase of the menstrual cycle,¹⁹ the follicular phase represents the physiological baseline of progesterone production by the adrenal glands. Given that the adrenal glands are capable of sustaining follicular levels of progesterone in premenopausal women, healthy adrenal glands are capable of maintaining follicular levels of progesterone in postmenopause women, as observed clinically. Phytotherapeutics that restore progesterone function will include phytoprogesterogen-ogenic herbs that optimize the healthy hormone producing function of the adrenal glands, the primary source of postmenopause progesterone.

The phytoprogesterogen-ogenic actions of Bupleurum (*Bupleurum falcatum*) are attributable to the ability of

saikogenin A, to increase ACTH levels,²⁰ since ACTH can increase progesterone levels.²¹ The ability to stimulate the hypothalamic-pituitary-adrenal system by promoting ACTH release maintains the size and function of the adrenal glands. The anti-inflammatory actions of saikogenin A mimic the anti-inflammatory functions of progesterone. Bupleurum is also a functional mimetic of progesterone's ability to reduce asthma symptoms.^{22,23,24}

Phytoprogestogen-ogenic attributes may also be assigned to *Rehmannia* (*Rehmannia glutinosa*) due to its effects on the hypothalamic-pituitary-adrenal axis.^{25,26,27} In addition to mimicking the osteoblastic stimulating actions of progesterone, *Rehmannia* also inhibits osteoclastic activity, in effect preventing osteoporotic bone loss.²⁸ As previously noted, the active constituent of *Coleus forskohlii*, forskolin has a direct effect on progesterone producing tissues.^{29,30,31} Forskolin also exhibits progesterone mimetic properties such as antihypertensive³² and anti-allergic actions.³³ The progesterone mimetic properties of *Passiflora* (*Passiflora incarnata*), such as anti-asthmatic,³⁴ anxiolytic,³⁵ and sedative,³⁶ may be due to a benzoflavone moiety (BZF) isolated from *Passiflora*.³⁷ The anxiolytic effect of the flavonoid present in *Passiflora incarnata*, has been linked to an activation of the GABA(A) receptors, mimicking the GABA(A) agonist properties of progesterone.³⁸

The traditional use of *Vitex* (*Vitex agnus-castus*) as a progesterone enhancing herb may be due to its ability to stimulate progesterone receptor expression,³⁹ as well as its ability to eliminate deficits in the luteal progesterone synthesis.⁴⁰ Peony (*Paeonia lactiflora*), a common constituent of traditional formulas targeting dysmenorrhea and menorrhagia, may exert its effect on the hypothalamic-pituitary axis and may activate ovarian function.^{41,42,43} Though used primarily for its contribution to uterine health, peony also has cognitive enhancing and significant antioxidant attributes.^{44,45} The beneficial effect that progesterone has on uterine health is mimicked in part by the actions of *Vitex* and Peony.

The antispasmodic and anti-inflammatory properties of Wild Yam (*Dioscorea villosa*) in many ways mimic the same actions of progesterone. Though traditionally considered a progestogenic herb, recent findings show that diosgenin causes coronary artery relaxation in which neither estrogen or progesterone receptors are involved.⁴⁶ Historically, the actions of *Dioscorea* have been attributed to an ability to relax the autonomic nervous system and therefore decrease vasomotor symptoms such as hot flushes and night sweats which are associated with autonomic dysfunction,^{47,48} suggesting it acts more as a functional mimetic of progesterone.

Phytotherapeutics to Restore Optimal Testosterone Function

If asked what the most important feature of testosterone was, most patients today would indicate its contribution to optimal sexual function in both genders. While phytotherapeutics targeted to improve testosterone function

can contribute to optimal sexual function, they often improve other important functions of testosterone as well, such as increased stress adaptation, an important function of testosterone in both genders.

Traditionally used for sexual debility, *Shatavari* (*Asparagus racemosus*) exhibits actions similar to acetylcholine,⁴⁹ a neurotransmitter involved in the sexual arousal response. The adaptogenic, anti-stress and immuno-stimulating activity of *Shatavari* has been validated in animal studies, and has the ability to provide antioxidant protection to neuronal tissues.^{50,51}

Damiana (*Turnera diffusa*) is widely used in the traditional medicine as an aphrodisiac, an attribute confirmed by animal studies, which demonstrated that *Damiana* acts as a sexual stimulant.⁵² Its ability to enhance engorgement or erectile tissue is associated with its vasodilatory abilities.⁵³ However, no androgen receptor interactions have been documented, suggesting *Damiana* is a functional mimetic of testosterone.

Epimedium (*Epimedium sagittatum*), also called "Horny Goat Weed" has traditionally been used for sexual dysfunction, fatigue and libido enhancement. *Epimedium* has been shown to improve sexual function and quality of life even in patients with chronic disease.⁵⁴ The effects of *Epimedium* are attributed to icariin, cGMP-specific PDE5 inhibitor that affects both the male and female sexual response.⁵⁵⁻⁵⁹ Though *Epimedium* has no demonstrable androgen effects, it does have glucocorticoid antagonist properties,⁶⁰ which may allow for a relative increase in androgen function.

The demonstrable ability of *Maca* (*Lepidium meyenii*) to enhance fertility in both men⁶¹ and women⁶² and improve sexual desire is not related to changes in pituitary or gonadal hormones.^{63,64} *Maca* does not activate androgen receptors⁶⁵ and may actually block androgen receptors.⁶⁶ The properties of *Maca* may be due to the presence of tetrahydro-beta-carbolines,⁶⁷ the same neuroactive alkaloids found in chocolate and cocoa,⁶⁸ which exert potent serotonin agonist actions.⁶⁹ Improvement of L-arginine-nitric oxide activity has also been attributed to *Maca*.⁷⁰ At best, *Maca* is a functional mimetic of testosterone.

Mucuna (*Mucuna pruriens*) is recognized as an aphrodisiac in Ayurvedic Medicine, used for both men and women with low libido, and for women undergoing menopause. Significant increase of sexual behavior through enhanced libido has been attributed to L-dopa, a constituent of *Mucuna*.^{71,72,73} The sexual response functions of L-dopa are enhanced by the presence of testosterone,^{74,75} revealing androgen agonist activities. The growth hormone secretagogue⁷⁶ actions of L-dopa may also be contributory.

Tribulus (*Tribulus terrestris*) is another herb used in Ayurvedic medicine that is considered to be a reproductive tonic. Though animal studies have demonstrated androgen increasing properties of *Tribulus*,^{77,78} subsequent human studies suggest that *Tribulus terrestris* steroid saponins

Continued on page 6

Women, Take Heart. Soy Isoflavones as Self-Care for Menopausal Symptoms and Disease Risks.

Dr. Ronald Klatz and Dr. Bob Goldman

Heart disease is the number one killer of American women and is responsible for half of all the deaths of women over age fifty. Ironically, in past years women were rarely included in clinical heart studies, but finally physicians have realized that it is as much a woman's disease as a man's. Postmenopausal women face at least fifteen times the risk of dying of heart disease than of an estrogen-dependent cancer. Indeed, research suggests that two isoflavones present in soy – genistein and daidzein – appear to lower a woman's risk of developing hormone-related diseases such as breast cancer and endometriosis. Results from one study revealed that women who ate the most soy and other phytoestrogen-rich foods were 54% less likely to develop endometrial cancer. Researchers believe that genistein, which has been shown to inhibit angiogenesis, may also block the protein tyrosine kinase, which promotes the growth and proliferation of tumor cells. Meanwhile, results of research published in 2002 revealed that women who eat soybeans and soy-based foods have significantly less "high risk" dense breast tissue, which is linked to breast cancer. In fact, women who consumed the most soy were 60% less likely to have dense breast tissue than women who ate the least. Soy isoflavone supplements are now available and may confer similar health benefits as the isoflavones found naturally in soy foods.

Menopause brings changes in the level of fats – lipids – in a woman's blood. In menopausal women, levels of LDL ("bad") cholesterol increase, while HDL ("good") cholesterol decreases, both as a direct result of estrogen. A meta-analysis conducted by Dr. Anderson and colleagues of the Veterans Affairs Medical Center (Lexington, Kentucky USA) on 38 independent studies revealed that soy consumption reduced cholesterol levels in 89% of the studies. The analysis, which concluded that "soy protein... significantly decreased serum concentrations of total cholesterol, LDL cholesterol, and triglycerides without significantly affecting serum HDL cholesterol concentrations," revealed that women who ate soy could, on average, expect a cholesterol reduction of 23 mg per deciliter.

Estrogen is beneficial for women who are at great risk for stroke or hypertension because it raises the HDL cholesterol level and lowers the LDL cholesterol, decreases the risk of heart attack, and does not elevate blood pressure. A 2002 study conducted at the University of Baskent (Turkey) found that estrogen also reduces homocysteine levels. Elevated levels of homocysteine, an amino acid formed when other amino acids in the blood are broken down by normal metabolic processes, are considered a major risk factor for heart disease. Yet, Estrogen Replacement Therapy (ERT) is not appropriate for every woman. Instead, some women may consider supplementation with soy isoflavones which exert a mild estrogenic activity and thus can be one way in which women can naturally raise their estrogen levels.

Soy isoflavones may also reduce the risk of hormone-dependent cancers. A study by Dr. Messina and team of the National Cancer Institute (National Institutes of Health, USA), found that 65% of 26 animal-based cancer studies demonstrated a protective effect of soy or soy isoflavones. Human research also suggests a protective role of soy against

cancer, as pointed out by studies including those by Dr. Aldercreutz (University of Helsinki, Finland) and Dr. Lee (National University of Singapore).

Soy isoflavones have also been found to directly improve menopausal symptoms. In a study by Dr. Albertazzi and colleagues of University of Ferrara (Italy), supplementation with 60 grams of soy protein per day for 12 weeks led to a 45% decrease in the number of hot flashes (compared to a 30% reduction in the placebo group). Isoflavones are also valuable in osteoporosis prevention. Dr. Potter and team of University of Illinois at Urbana-Champaign (USA) found that supplementation with 40 grams of soy protein powder per day (containing 90 mg of isoflavones per day) was protective against bone mineral loss in the spine.

Soy isoflavones may represent one of the most potent self-care options for menopause. The benefits perhaps are best and simply stated by Dr. Han and team from Escola Paulista de Medicina/Federal University of Sao Paulo (Brazil). They followed 80 women who consumed soy isoflavones for four months, finding that "total cholesterol and low-density lipoprotein decreased significantly," without any adverse effects on blood pressure, plasma glucose, and high-density lipoprotein. Dr. Han's group concluded that "[a] isoflavone 100-mg regime treatment may be a safe and effective alternative therapy for menopausal symptoms and may offer a benefit to the cardiovascular system."

REFERENCES

- Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. *Lancet* 1993;342:1209-10.
- Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flashes. *Obstet Gynecol* 1998;91:6-11.
- Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. *N Engl J Med* 1995;333:276-82.
- Han KK, Soares JM Jr, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. *Obstet Gynecol* 2002;99:389-94.
- Klatz R and Goldman R. *The New Anti-Aging Revolution*. Basic Health Publications, 2003.
- Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast-cancer risk in Singapore. *Lancet* 1991;337:1197-200.
- Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. *Nutr Cancer* 1994;21:113-31.
- Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr* 1998;68(suppl):1375S-79S.

Dr. Ronald Klatz and Dr. Bob Goldman are physicians and co-founders of the anti-aging medical movement and of the American Academy of Anti-Aging Medicine (A4M; Chicago, IL USA; www.worldhealth.net), a non-profit medical organization dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on anti-aging issues.

Phytotherapeutic Management of Endocrine Dysfunction – Continued from page 4

possess neither direct nor indirect androgen-increasing properties.⁷⁹ The ability of Tribulus to increase the release of nitric oxide may account for its claims as an aphrodisiac.^{80,81}

Ashwagandha (*Withania somnifera*), also commonly used in Ayurvedic medicine, is best regarded as adaptogen^{82,83} with aphrodisiac properties, which may be due to increased interstitial cell stimulating hormone and testosterone-like effects⁸⁴ as well as the induction of nitric oxide synthase.⁸⁵ The antistressor properties, due to anxiolytic GABA-mimetic activity⁸⁶ which act independent of GABA receptors,^{87,88,89} may be contributory.

Eleutherococcus senticosus, has no documented androgen properties. The anti-fatigue, anti-stress, immunoenhancing effect, enhanced neuro-cognitive, and anti-depressive effects associated with regular use may be associated with effects on the hypothalamic-pituitary-adrenal (HPA) axis, which plays a primary role in the reactions of the body to repeated stress and adaptation to stressors.^{90,91,92} Increased nitric oxide and enhanced acetylcholine function contribute to improved sexual function.^{93,94}

Phytotherapeutics to Quench Excessive Testosterone Function

Androgen excess, affecting up to 10% of women, places these women at great risk for insulin resistance, diabetes, dyslipidemias, cancers and cardiovascular disease.^{95,96} Phytoantiandrogens are a class of phyto-compounds that decrease tissue sensitivity to androgens or decrease androgen activity, often through 5-alpha-reductase inhibition, which decreases conversion of testosterone to the more androgenic dihydrotestosterone. These actions are most likely due to the presence of free fatty acids such as palmitic-acid and stearic-acid as well as the phytosterol beta-sitosterol, all of which have 5-alpha-reductase inhibiting activity.^{97,98,99} These three constituents are present in *Serenoa repens*, *Ocimum sanctum* and *Trigonella foenum-graecum*. Palmitic acid is also an active component within *Foeniculum vulgare* and *Urtica dioica*. *Foeniculum vulgare* and *Pygeum africanum* also contain beta-sitosterol.^{98,99} Some phytoantiandrogens also have antihyperglycemic, antihyperlipidemic, and anti-inflammatory properties, all of which greatly benefit women with hyperandrogenism.

Saw Palmetto's (*Serenoa repens*) antiandrogenic properties are attributed to inhibitory effects on 5-alpha-reductase due to a high content in the free fatty acids and beta-sitosterol.^{100,101} Anti-inflammatory properties have also been noted in *Serenoa repens*.¹⁰²

Fennel (*Foeniculum vulgare*), traditionally considered an anti-androgen, has demonstrable anti-hirsutism and anti-inflammatory properties^{103,104} in part due to palmitic acid and beta-sitosterol. The anti-androgen properties of Nettles

(*Urtica dioica*) may be due to palmitic acid, as well as other free fatty acids such as oleic acid, linoleic acid and linolenic acid.^{98,99} Antihyperglycemic and anti-inflammatory effects have also been demonstrated for *Urtica dioica*.^{105,106,107}


Holy Basil (*Ocimum sanctum*) displays significant anti-androgenic affect in androgen responsive tissues, an effect that was reversible and returned to normal two weeks after the withdrawal of treatment.^{108,109} Sedative properties have also been identified in *Ocimum sanctum*, an adaptogen in Ayurvedic medicine which demonstrates antistressor properties to adverse stimuli as well as toxic substances.^{110,111,112} Anti-inflammatory, antihyperglycemic and antihyperlipidemic action have also been documented in Holy Basil.¹¹³⁻¹¹⁸

Fenugreek (*Trigonella foenum-graecum*) has anti-androgen activities, due to beta-sitosterol, palmitic-acid and stearic-acid, and also has the ability to lower total cholesterol, LDL, VLDL cholesterol and triglycerides significantly.¹¹⁹⁻¹²² The anti-hyperglycemic and anti-inflammatory properties noted in fenugreek are of additional benefit.^{123,124}

The anti-androgen properties of Pygeum (*Pygeum africanum*) may be due to beta-sitosterol and other sterols that suppress the effects of dihydrotestosterone.^{99,125} Anti-inflammatory properties have also been documented in Pygeum.¹²⁶

Conclusion

Phytotherapeutic management of endocrine dysfunction allows clinicians hormone-free choices for addressing conditions associated with suboptimal estrogen, progesterone and androgen function such as some cases of menopause and some forms of PMS & PMDD. Andropause can be managed without the risks of testosterone replacement therapy. Androgen excess disorders, seen in some menopause cases, some forms of PMS/PMDD as well as PCOS and PCO-like syndrome can effectively be managed with phytoantiandrogens.

As phytotherapeutic research continues, current understanding of the mechanisms by which plant derived substances affect the endocrine system will be expanded. All indications are that increased understanding of the affect that phytotherapeutic agents have on androgen, estrogen and progesterone function will allow individuals with endocrine dysfunction more hormone-free options that significantly impact quality of life and risk of disease. 

References:

(NOTE: PMID refers to Pub Med Identification number at www.pubmed.gov)

- 1 Al-Qarawi AA, Abdel-Rahman HA, El-Badry AA, Harraz F, Razig NA, Abdel-Magied EM. The effect of extracts of *Cynomorium coccineum* and *Withania somnifera* on gonadotrophins and ovarian follicles of immature Wistar rats. *Phytother Res*. 2000 Jun;14(4):288-90. [PMID:10861976]
- 2 Chang LL, Kau MM, Wun WS, Ho LT, Wang PS. Effects of fasting on corticosterone production by zona fasciculata-reticularis cells in ovariectomized rats. *J Investig Med*. 2002 Mar;50(2):86-94. [PMID:11928947]
- 3 McAllister JM, Hornsby PJ. TPA inhibits the synthesis of androgens and cortisol and enhances the synthesis non-17 alpha-hydroxylated steroids in cultured human adrenocortical cells. *Endocrinology*. 1987 Nov;121(5):1908-10. [PMID:3499311]
- 4 Anbarasi K, Vani G, Balakrishna K, Devi CS. Effect of bacoside A on brain antioxidant status in cigarette smoke exposed rats. *Life Sci*. 2005 Oct 11. [PMID:16226278]
- 5 Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W. *Cimicifuga racemosa* extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. *Phytomedicine*. 2005 Mar;12(3):178-82. [PMID:15830838]
- 6 Stromeier S, Peterleit F, Nahrstedt A. Phenolic esters from the rhizomes of *Cimicifuga racemosa* do not

- cause proliferation effects in MCF-7 cells. *Planta Med*. 2005 Jun;71(6):495-500. [PMID: 15971118]
- 7 Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W. Evidence for selective estrogen receptor modulator activity in a black cohosh (*Cimicifuga racemosa*) extract: comparison with estradiol-17 β . *Eur J Endocrinol*. 2003 Oct;149(4):351-62. [PMID: 14514351].
- 8 Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine*. 2001 Sep;8(5):401-9. [PMID: 11695885].
- 9 Hsieh MT, Wu CR, Wang WH, Lin LW. The ameliorating effect of the water layer of *Fructus Schisandrae* on cycloheximide-induced amnesia in rats: interaction with drugs acting at neurotransmitter receptors. *Pharmacol Res*. 2001 Jan;43(1):17-22. [PMID: 11207061].
- 10 Lee YJ, Cho JY, Kim JH, Park WK, Kim DK, Rhyu MR. Extracts from *Schizandra chinensis* fruit activate estrogen receptors: a possible clue to its effects on nitric oxide-mediated vasorelaxation. *Biol Pharm Bull*. 2004 Jul;27(7):1066-9. [PMID: 15256741].
- 11 Bagchi D, Sen CK, Bagchi M, Atalay M. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. *Biochemistry (Mosc)*. 2004 Jan;69(1):75-80, 1 p preceding 75. [PMID: 14572022].
- 12 Reed J. Cranberry flavonoids, atherosclerosis and cardiovascular health. *Crit Rev Food Sci Nutr*. 2002;42(3 Suppl):301-16. [PMID: 12058989].
- 13 Manthey D, Behl C. From structural biochemistry to expression profiling: Neuroprotective activities of estrogen. *Neuroscience*. 2005 Dec 9. [PMID: 16343783].
- 14 Anbarasi K, Yani G, Balakrishna K, Devi CS. Effect of bacouide A on brain antioxidant status in cigarette smoke exposed rats. *Life Sci*. 2005 Oct 11. [PMID: 16226278].
- 15 Russo A, Borrelli F. *Bacopa monniera*, a reputed nootropic plant: an overview. *Phytomedicine*. 2005 Apr;12(4):305-17. [PMID: 15898709].
- 16 Liu J, Burdette JE, Xu H, Gu C, van Breenen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *J Agric Food Chem*. 2001 May;49(5):2472-9. [PMID: 11368622].
- 17 Hirata JD, Swiersz LM, Zell B, Small R, Etinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. *Fertil Steril*. 1997 Dec;68(6):981-6. [PMID: 9418683].
- 18 Sassa S, Kikuchi T, Shinoda H, Suzuki S, Kudo H, Sakamoto S. Preventive effect of ferulic acid on bone loss in ovariectomized rats. *In Vivo*. 2003 May-Jun;17(3):277-80. [PMID: 12929580].
- 19 Zumoff B, Miller L, Levin J, Levit CD, Miller EH, Heinz U, Kalin M, Denman H, Jandorek R, Rosenfeld RS. Follicular-phase serum progesterone levels of nonsmoking women do not differ from the levels of nonsmoking men. *Steroids*. 1990 Dec;55(12):557-9. [PMID: 2089746].
- 20 Cheng JT, Tsai CL. Anti-inflammatory effect of saikogenin A. *Biochem Pharmacol*. 1986 Aug 1;35(15):2483-7. [PMID: 2427082].
- 21 De Geyter C, De Geyter M, Huber PR, Nieschlag E, Holzgreve W. Progesterone serum levels during the follicular phase of the menstrual cycle originate from the cross-talk between the ovaries and the adrenal cortex. *Hum Reprod*. 2002 Apr;17(4):933-9. [PMID: 11925385].
- 22 Park KH, Park J, Koh D, Lim Y. Effect of saikosaponin-A, a triterpenoid glycoside, isolated from *Bupleurum falcatum* on experimental allergic asthma. *Phytother Res*. 2002 Jun;16(4):359-63. [PMID: 12112293].
- 23 Mishuk VP, Saipin SR. Endocrine mechanisms of the pathogenesis of nocturnal asthma. *Probl Tuberk Bolezni Legk*. 2005;8(5):57-60. [PMID: 16209024].
- 24 Lam SM, Huang SC. Premenstrual asthma: report of a case with hormonal studies. *J Microbiol Immunol Infect*. 1998 Sep;31(3):197-9. [PMID: 10496158].
- 25 Cha Liang-Lun, et al: 880778, Abstracts of Chinese Medicine Vol.2, No3, Nov. (1988).
- 26 Zha LL, Zhong Xi Yi Jie He Za Zhi. 1988 Feb;8(2):95-7. Experimental effect of *Rehmannia glutinosa* on the pituitary and adrenal cortex in a glucocorticoid inhibition model using rabbits. [PMID: 3409436].
- 27 Zhang R, Zhou J, Jia Z, Zhang Y, Gu G. Hypoglycemic effect of *Rehmannia glutinosa* oligosaccharide in hyperglycemic and alloxan-induced diabetic rats and its mechanism. *J Ethnopharmacol*. 2004 Jan;90(1):39-43. [PMID: 14698506].
- 28 Oh KO, Kim SW, Kim JY, Ko SY, Kim HM, Baek JH, Ryou HM, Kim JK. Effect of *Rehmannia glutinosa* Libosch extracts on bone metabolism. *Clin Chim Acta*. 2003 Aug;334(1-2):185-95. [PMID: 12867291].
- 29 Chang LL, Kau MM, Wun WS, Ho LT, Wang PS. Effects of fasting on corticosterone production by zona fasciculata-reticularis cells in ovariectomized rats. *J Investig Med*. 2002 Mar;50(2):86-94. [PMID: 11928947].
- 30 McAllister JM, Hornsby PJ. TPA inhibits the synthesis of androgens and cortisol and enhances the synthesis non-17 α -hydroxylated steroids in cultured human adrenocortical cells. *Endocrinology*. 1987 Nov;121(5):1908-10. [PMID: 3499311].
- 31 Ben-Shlomo I, Goldman S, Shalev E. Regulation of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of MMP, and progesterone secretion in luteinized granulosa cells from normally ovulating women with polycystic ovary disease. *Fertil Steril*. 2003 Mar;79 Suppl 1:694-701. [PMID: 12620479].
- 32 Lindner E, Dohadwalla AN, Bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from *Coleus forskohlii*: Forskolin. *Arzneimittelforschung*. 1978;28(2):284-9. [PMID: 580393].
- 33 Kreutner W, Chapman RW, Gulbenkian A, Tozzi S. Bronchodilator and anti-allergy activity of forskolin. *Eur J Pharmacol*. 1985 Apr 23;111(1):1-8. [PMID: 2410281].
- 34 Dhawan K, Kumar S, Sharma A. Antispasmodic activity of the methanol extract of leaves of *Passiflora incarnata*. *Phytother Res*. 2003 Aug;17(7):821-2. [PMID: 12916087].
- 35 Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of *Passiflora incarnata* Linnaeus. *J Ethnopharmacol*. 2001 Dec;78(2-3):165-70. [PMID: 11694362].
- 36 Krenn L. Passion Flower (*Passiflora incarnata* L.)—a reliable herbal sedative. *Wien Med Wochenschr*. 2002;152(15-16):404-6. [PMID: 12244887].
- 37 Dhawan K, Kumar S, Sharma A. Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats. *J Med Food*. 2002 Spring;5(1):43-8. [PMID: 12511112].
- 38 Lancel M, Faulhaber J, Holsboer F, Rupprecht R. Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. *Am J Physiol*. 1996 Oct;271(4 Pt 1):E763-72. [PMID: 8897866].
- 39 Liu J, Burdette JE, Xu H, Gu C, van Breenen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *J Agric Food Chem*. 2001 May;49(5):2472-9. [PMID: 11368622].
- 40 Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, Schmitz H. Vitec agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. *Arzneimittelforschung*. 1993 Jul;43(7):752-6. [PMID: 8369008].
- 41 Bensky D, Gamble A, Kaptchuk T. *Chinese Herbal Medicine Materia Medica*, rev ed, Seattle: Eastland Press, 1993:331-2.
- 42 Sakamoto S, Yoshino H, Shirahata Y, Shimodaira K, Okamoto R. Pharmacotherapeutic effects of kwei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas. *Am J Chin Med*. 1992;20(3-4):313-7. [PMID: 1471615].
- 43 Koyama T, Ohara M, Ichimura M, Saito M. Effect of Japanese kampo medicine on hypothalamic-pituitary-ovarian function in women with ovarian insufficiency. *Am J Chin Med*. 1988;16(1-2):47-55. [PMID: 3218631].
- 44 Watanabe H. Candidates for cognitive enhancer extracted from medicinal plants: paeoniflorin and tetramethylpyrazine. *Behav Brain Res*. 1997 Feb;83(1-2):135-41. [PMID: 9062672].
- 45 Kang JH, Park YH, Choi SW, Yang EK, Lee WJ. Resveratrol derivatives potentially induce apoptosis in human promyelocytic leukemia cells. *Exp Mol Med*. 2003 Dec 31;35(6):467-74. [PMID: 14749523].
- 46 Au AL, Kwok CC, Lee AT, Kwan YW, Lee MM, Zhang RZ, Ngai SM, Lee SM, He GW, Fung KP. Activation of iberiotoxin-sensitive, Ca $^{2+}$ -activated K $^{+}$ channels of porcine isolated left anterior descending coronary artery by diosgenin. *Eur J Pharmacol*. 2004 Oct 11;502(1-2):123-33. [PMID: 15464098].
- 47 Willard, T, 1992, Textbook of Advanced Herbology, Wild Rose College of Natural Healing, Alberta, Canada, p 123.
- 48 Priest, AW, Priest, LR, 1982, Herbal Medication, LN Fowler and Co. Ltd., Essex, p. 68.
- 49 Goyal RK, Singh J, Lal H. *Asparagus racemosus* an update. *Indian J Med Sci*. 2003 Sep;57(9):408-14. [PMID: 14515032].
- 50 Rege NN, Thatte UM, Dahanurkar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. *Phytother Res*. 1999 Jun;13(4):275-91. [PMID: 10404532].
- 51 Parihar MS, Hemnani T. Experimental excitotoxicity provokes oxidative damage in mice brain and attenuation by extract of *Asparagus racemosus*. *J Neural Transm*. 2004 Jan;111(1):1-12. Epub 2003 Dec 3. [PMID: 14714211].
- 52 Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A. Stimulating property of *Turnera diffusa* and *Passiflora paniculata* extracts on the sexual-behavior of male rats. *Psychopharmacology (Berl)*. 1999 Mar;143(1):15-9. [PMID: 10227074].
- 53 Hnatyszyn O, Moscatelli V, Garcia J, Rondina R, Costa M, Arranz C, Balaszczuk A, Ferraro G, Coussio JD. Argentinian plant extracts with relaxant effect on the smooth muscle of the corpus cavernosum of guinea pig. *Phytomedicine*. 2003 Nov;10(8):669-74. [PMID: 14692728].
- 54 Liao HJ, Chen XM, Li WG. Effect of *Epidemium sagittatum* on quality of life and cellular immunity in patients of hemodialysis maintenance. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 1995 Apr;15(4):202-4. [PMID: 7647539].
- 55 Mao H, Zhang L, Wang Y, Li X. Experimental studies of icariin on anticancer mechanism. *Zhong Yao Cai*. 2000 Sep;23(9):554-6. [PMID: 12575282].
- 56 Zhao Y, Cui Z, Zhang L. Effects of icariin on the differentiation of HL-60 cells. *Zhonghua Zhong Liu Za Zhi*. 1997 Jan;19(1):53-5. [PMID: 10743057].
- 57 Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. *Asian J Androl*. 2003 Mar;5(1):15-8. [PMID: 12646997].
- 58 D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA. Type 5 phosphodiesterase expression in the human vagina. *Urology*. 2002 Jul;60(1):191-5. [PMID: 12100961].
- 59 Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. *Asian J Androl*. 2005 Dec;7(4):381-8. [PMID: 16281085].
- 60 Wu T, Cui L, Zhang Z, Chen Z, Li Q, Liao J, Huang L. Experimental study on antagonizing action of herba *Epidemii* on side effects induced by glucocorticoids. *Zhongguo Zhong Yao Za Zhi*. 1996 Dec;21(12):748-51, 763. [PMID: 9812684].
- 61 Gonzales GF, Cordova A, Vega K, Chung A, Villena A, Gonez C. Effect of *Lepidium meyenii* (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men. *J Endocrinol*. 2003 Jan;176(1):163-8. [PMID: 12525260].
- 62 Ruiz-Luna AC, Salazar S, Aspajo NJ, Rubio J, Gasco M, Gonzales GF. *Lepidium meyenii* (Maca) increases litter size in normal adult female mice. *Reprod Biol Endocrinol*. 2005 May 3;3(1):16. [PMID: 15869705].
- 63 Gonzales GF, Cordova A, Gonzales C, Chung A, Vega K, Villena A. *Lepidium meyenii* (Maca) improved semen parameters in adult men. *Asian J Androl*. 2001 Dec;3(4):301-3. [PMID: 11753476].
- 64 Gonzales GF, Cordova A, Vega K, Chung A, Villena A, Gonez C, Castillo S. Effect of *Lepidium meyenii* (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. *Andrologia*. 2002 Dec;34(6):367-72. [PMID: 12472620].
- 65 Bogani P, Simonini F, Iriti M, Rossoni M, Faoro F, Poletti A, Visioli F. *Lepidium meyenii* (Maca) does not exert direct androgenic activities. *J Ethnopharmacol*. 2005 Oct 17. [PMID: 16239088].
- 66 Gonzales GF, Miranda S, Nieto J, Fernandez G, Yucra S, Rubio J, Yi P, Gasco M. Red maca (*Lepidium meyenii*) reduced prostate size in rats. *Reprod Biol Endocrinol*. 2005 Jan 20;3(1):5. [PMID: 15661081].
- 67 Piacente S, Carbone V, Plaza A, Zampelli A, Pizza C. Investigation of the tuber constituents of maca (*Lepidium meyenii* Walp.). *J Agric Food Chem*. 2002 Sep 25;50(20):5621-5. [PMID: 12236688].
- 68 Herraiz T. Tetrahydro-beta-carbolines, potential neuroactive alkaloids, in chocolate and cocoa. *J Agric Food Chem*. 2000 Oct;48(10):4900-4. [PMID: 11052752].
- 69 Nielsen EB, White FJ, Holohean AM, Callahan PM, Appel JB. Behavioral and biochemical evidence for serotonergic actions of tetrahydro-beta-carbolines. *Life Sci*. 1982 Nov 29;31(22):2433-9. [PMID: 7154844].
- 70 McKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. *Altern Med Rev*. 2004 Mar;9(1):4-16. [PMID: 15005641].
- 71 Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. *Br J Psychiatry*. 1988 Dec;153:833-6. [PMID: 3256388].
- 72 Berger C, Mehrhoff FW, Beier KM, Meincik HM. Sexual delinquency and Parkinson's disease. *Nervenarzt*. 2003 Apr;74(4):370-5. [PMID: 12707708].
- 73 Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. *J Neural Sci*. 2000 Jun 15;176(2):124-7. [PMID: 10930594].
- 74 Horita H, Sato Y, Adachi H, Suzuki N, Kato R, Hisasue S, Suzuki K, Tsukamoto T. Effects of levodopa on nocturnal penile tumescence: a preliminary study. *J Androl*. 1998 Sep-Oct;19(5):619-24. [PMID: 9796623].
- 75 Szczytko MS, Zhou QY, Palminter RD. Dopamine-stimulated sexual behavior is testosterone dependent in mice. *Behav Neurosci*. 1998 Oct;112(5):1229-35. [PMID: 9829800].
- 76 Maurus N, Walton P, Nicar M, Welch S, Rogal AD. Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. *Pediatr Res*. 2000 Nov;48(5):614-8. [PMID: 11044480].
- 77 Gauthaman K, Adaikan PG, Prasad RN. Aphrodisiac properties of *Tribulus Terrestris* extract (Protodioscin) in normal and castrated rats. *Life Sci*. 2002 Aug 9;71(12):1385-96. [PMID: 12127159].
- 78 Gauthaman K, Adaikan PG. Effect of *Tribulus terrestris* on nicotinamide adenine dinucleotide phosphate-diaphorase activity and androgen receptors in rat brain. *J Ethnopharmacol*. 2005 Jan 4;96(1):1-27-32. [PMID: 15588660].
- 79 Neychev VK, Mitev VI. The aphrodisiac herb *Tribulus terrestris* does not influence the androgen production in young men. *J Ethnopharmacol*. 2005 Oct 3;101(1-3):319-23. [PMID: 15994038].
- 80 Gauthaman K, Ganesan AP, Prasad RN. Sexual effects of puncturevine (*Tribulus terrestris*) extract (protodioscin): an evaluation using a rat model. *J Altern Complement Med*. 2003 Apr;9(2):257-65. [PMID: 12804079].
- 81 Adaikan PG, Gauthaman K, Prasad RN, Ng SC. Proerectile pharmacological effects of *Tribulus terrestris* extract on the rabbit corpus cavernosum. *Ann Acad Med Singapore*. 2000 Jan;29(1):22-6. [PMID: 10748960].
- 82 Archana R, Namasivayam A. Antistressor effect of *Withania somnifera*. *J Ethnopharmacol*. 1999 Jan;64(1):91-3. [PMID: 10075127].
- 83 Dhuley JN. Adaptogenic and cardioprotective action of ashwagandha in rats and frogs. *J Ethnopharmacol*. 2000 Apr;70(1):57-63. [PMID: 10720789].
- 84 Abdel-Magied EM, Abdel-Rahman HA, Harraz FM. The effect of aqueous extracts of *Cynomorium coccineum* and *Withania somnifera* on testicular development in immature Wistar rats. *J Ethnopharmacol*. 2001 Apr;75(1):1-4. [PMID: 11282435].
- 85 Iuvone T, Esposito G, Capasso F, Izzo AA. Induction of nitric oxide synthase expression by *Withania somnifera* in macrophages. *Life Sci*. 2003 Feb 21;72(14):1617-25. [PMID: 12551750].
- 86 Mehta AK, Binkley P, Gandhi SS, Ticku MK. Pharmacological effects of *Withania somnifera* root extract on GABAA receptor complex. *Indian J Med Res*. 1991 Aug;94:312-5. [PMID: 1660034].
- 87 Jain S, Shukla SD, Sharma K, Bhatnagar M. Neuroprotective effects of *Withania somnifera* Dunn. in hippocampal sub-regions of female albino rat. *Phytother Res*. 2001 Sep;15(6):544-8. [PMID: 11536389].
- 88 Mehta AK, Binkley P, Gandhi SS, Ticku MK. Pharmacological effects of *Withania somnifera* root extract on GABAA receptor complex. *Indian J Med Res*. 1991 Aug;94:312-5. [PMID: 1660034].
- 89 Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and *Shilajit* differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochem Int*. 1997 Feb;30(2):181-90. [PMID: 9017665].
- 90 Deyama T, Nishibe S, Nakazawa Y. Constituents and pharmacological effects of *Eucommia* and

- Siberian ginseng. *Acta Pharmacol Sin.* 2001 Dec;22(12):1057-70. [PMID: 11749801]
- 91 Panossian A, Wagner H. Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. *Phytother Res.* 2005 Oct;19(10):819-38. [PMID: 16261511]
- 92 Kimura Y, Sumiyoshi M. Effects of various *Eleutherococcus senticosus* cortex on swimming time, natural killer activity and corticosterone level in forced swimming stressed mice. *J Ethnopharmacol.* 2004 Dec;95(2-3):447-53. [PMID: 15507373]
- 93 Kwan CY, Zhang WB, Sim SM, Deyama T, Nishibe S. Vascular effects of Siberian ginseng (*Eleutherococcus senticosus*): endothelium-dependent NO- and EDHF-mediated relaxation depending on vessel size. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2004 May;369(5):473-80. Epub 2004 Apr 17. [PMID: 15095033]
- 94 Sandroni P. Aphrodisiacs past and present: a historical review. *Clin Auton Res.* 2001 Oct;11(5):303-7. [PMID: 11758796]
- 95 Beckers A, Parotte MC, Gaspard U, Khalife A. Hyperandrogenism: clinical aspects, investigation and treatment. *Rev Med Liege.* 1999 Apr;54(4):274-82. [PMID: 10389470]
- 96 Derman RJ. Androgen excess in women. *Int J Fertil Menopausal Stud.* 1996 Mar-Apr;41(2):172-6. [PMID: 8829697]
- 97 Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. *J Altern Complement Med.* 2002 Apr;8(2):143-52. [PMID: 12006122]
- 98 Duke, James A. 1992. Handbook of phytochemical constituents of GRAS herbs and other economic plants. Boca Raton, FL. CRC Press.
- 99 Duke, James A. Dr. Duke's Phytochemical and Ethnobotanical Databases. www.ars-grin.gov/duke/
- 100 Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. *J Steroid Biochem Mol Biol.* 2002 Oct;82(2-3):233-9. [PMID: 12477490]
- 101 Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. *J Altern Complement Med.* 2002 Apr;8(2):143-52. [PMID: 12006122]
- 102 Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. *Arzneimittelforschung.* 1992 Apr;42(4):547-51. [PMID: 1642680]
- 103 Javidnia K, Dastgheib L, Mohammadi Samani S, Nasiri A. Antihirsutism activity of Fennel (fruits of *Foeniculum vulgare*) extract. A double-blind placebo controlled study. *Phytomedicine.* 2003;10(6-7):455-8. [PMID: 13678227]
- 104 Choi EM, Hwang JK. Antiinflammatory, analgesic and antioxidant activities of the fruit of *Foeniculum vulgare*. *Fitoterapia.* 2004 Sep;75(6):557-65. [PMID: 15351109]
- 105 Bnouham M, Merhfouf FZ, Ziyat A, Mekhfi H, Aziz M, Legssyer A. Antihyperglycemic activity of the aqueous extract of *Urtica dioica*. *Fitoterapia.* 2003 Dec;74(7-8):677-81. [PMID: 14630172]
- 106 Farzami B, Ahmadvand D, Vardasbi S, Majin FJ, Khaghani Sh. Induction of insulin secretion by a component of *Urtica dioica* leaf extract in perfused islets of Langerhans and its in vivo effects in normal and streptozotocin diabetic rats. *J Ethnopharmacol.* 2003 Nov;89(1):47-53. [PMID: 14522431]
- 107 Schulze-Tanzil G, de SP, Behnke B, Klingelhofer S, Scheid A, Shakibaei M. Effects of the antirheumatic remedy hox alpha—a new stinging nettle leaf extract—on matrix metalloproteinases in human chondrocytes in vitro. *Histol Histopathol.* 2002 Apr;17(2):477-85. [PMID: 11962753]
- 108 Ahmed M, Ahamed RN, Aladakkatti RH, Ghosesawar MG. Reversible anti-fertility effect of benzene extract of *Ocimum sanctum* leaves on sperm parameters and fructose content in rats. *J Basic Clin Physiol Pharmacol.* 2002;13(1):51-9. [PMID: 12099405]
- 109 Kantak NM, Gogate MG. Effect of short term administration of Tulsi (*Ocimum sanctum* Linn.) on reproductive behaviour of adult male rats. *Indian J Physiol Pharmacol.* 1992 Apr;36(2):109-11. [PMID: 1506071]
- 110 Sakina MR, Dandiyia PC, Hamdard ME, Hameed A. Preliminary psychopharmacological evaluation of *Ocimum sanctum* leaf extract. *J Ethnopharmacol.* 1990 Feb;28(2):143-50. [PMID: 2329804]
- 111 Sembulingam K, Sembulingam P, Namasivayam A. Effect of *Ocimum sanctum* Linn on noise induced changes in plasma corticosterone level. *Indian J Physiol Pharmacol.* 1997 Apr;41(2):139-43. [PMID: 9142558]
- 112 Sen P, Maiti PC, Puri S, Ray A, Audulov NA, Valdman AV. Mechanism of anti-stress activity of *Ocimum sanctum* Linn, eugenol and *Tinospora malabarica* in experimental animals. *Indian J Exp Biol.* 1992 Jul;30(7):592-6. [PMID: 1459632]
- 113 Kelm MA, Nair MG, Strasburg GM, DeWitt DL. Antioxidant and cyclooxygenase inhibitory phenolic compounds from *Ocimum sanctum* Linn. *Phytomedicine.* 2000 Mar;7(1):7-13. [PMID: 10782484]
- 114 Godhwani S, Godhwani JL, Vyas DS. *Ocimum sanctum*: an experimental study evaluating its anti-inflammatory, analgesic and antipyretic activity in animals. *J Ethnopharmacol.* 1987 Nov;21(2):153-63. [PMID: 3501819]
- 115 Singh S, Majumdar DK. Effect of *Ocimum sanctum* fixed oil on vascular permeability and leucocytes migration. *Indian J Exp Biol.* 1999 Nov;37(11):1136-8. [PMID: 10783746]
- 116 Sarkar A, Lavania SC, Pandey DN, Pant MC. Changes in the blood lipid profile after administration of *Ocimum sanctum* (Tulsi) leaves in the normal albino rabbits. *Indian J Physiol Pharmacol.* 1994 Oct;38(4):311-2. [PMID: 7883302]
- 117 Vats V, Grover JK, Rathi SS. Evaluation of anti-hyperglycemic and hypoglycemic effect of *Trigonella foenum-graecum* Linn, *Ocimum sanctum* Linn and *Pterocarpus marsupium* Linn in normal and alloxanized diabetic rats. *J Ethnopharmacol.* 2002 Jan;79(1):95-100. [PMID: 11744301]
- 118 Chattopadhyay RR. Hypoglycemic effect of *Ocimum sanctum* leaf extract in normal and streptozotocin diabetic rats. *Indian J Exp Biol.* 1993 Nov;31(11):891-3. [PMID: 8112763]
- 119 Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. *Eur J Clin Nutr.* 1990 Apr;44(4):301-6. [PMID: 2194788]
- 120 Stark A, Madar Z. The effect of an ethanol extract derived from fenugreek (*Trigonella foenum-graecum*) on bile acid absorption and cholesterol levels in rats. *Br J Nutr.* 1993 Jan;69(1):277-87. [PMID: 8457534]
- 121 Petit P, Sauvairé Y, Ponsin G, Manteghetti M, Fave A, Ribes G. Effects of a fenugreek seed extract on feeding behaviour in the rat: metabolic-endocrine correlates. *Pharmacol Biochem Behav.* 1993 Jun;45(2):369-74. [PMID: 8327543]
- 122 Hannan JM, Rokeya B, Faruque O, Nahar N, Masihuzzaman M, Azad Khan AK, Ali L. Effect of soluble dietary fibre fraction of *Trigonella foenum-graecum* on glycaemic, insulinemic, lipidemic and platelet aggregation status of Type 2 diabetic model rats. *J Ethnopharmacol.* 2003 Sep;88(1):73-7. [PMID: 12902054]
- 123 Gupta A, Gupta R, Lal B. Effect of *Trigonella foenum-graecum* (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. *J Assoc Physicians India.* 2001 Nov;49:1057-61. [PMID: 11868853]
- 124 Sur P, Das M, Gomes A, Vedasiromoni JR, Sahu NP, Banerjee S, Sharma RM, Ganguly DK. *Trigonella foenum-graecum* (fenugreek) seed extract as an antineoplastic agent. *Phytother Res.* 2001 May;15(3):257-9. [PMID: 11351364]
- 125 Yoshimura Y, Yamaguchi O, Bellamy F, Constantinou CE. Effect of *Pygeum africanum* tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. *Urology.* 2003 Feb;61(2):474-8. [PMID: 12597984]
- 126 Szolnoki E, Reichart E, Marchal S, Szegedi G. The effect of *Pygeum africanum* on fibroblast growth factor (FGF) and transforming growth factor beta (TGF beta 1/LAP) expression in animal model. *Acta Microbiol Immunol Hung.* 2001;48(1):1-9. [PMID: 11233693]

About the Author

Joseph J. Collins, N.D.

Dr. Collins is licensed by the state of Washington as a naturopathic physician. His experiences focus on integrative functional endocrinology. He has established effective protocols for optimizing endocrine function through the use of specific phytoestrogen, phyto-androgen, phytoprogesterone, and phyto-antiandrogen herbal formulations. He is the author of *Discover Your Menopause Type*, a book used by healthcare professionals and women to create personalized protocols for menopause.

For more information on phytocrinology and Dr. Collins protocols, see <http://www.phytocrine.com>